Physician profile
Anna D Guanche
NPI 1982658761
$80,555.12
in general payments reported to CMS, 2019-2025
22 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,788 · 2020: $144 · 2021: $12K · 2022: $12K · 2023: $22K · 2024: $15K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $2,973 · Travel and Lodging: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,612.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,000.00 |
| Food and Beverage | $2,973.26 |
| Travel and Lodging | $110.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31,985.03 | 2022-2025 | |
| Allergan, INC. | $15,466.73 | 2019-2022 | |
| Musculoskeletal Transplant Foundation INC. | $13,522.01 | 2021-2024 | |
| Galderma Laboratories, L.P. | $13,023.62 | 2019-2025 | |
| Merz North America, INC. | $5,691.73 | 2021-2023 | Xeomin |
| Sun Pharmaceutical Industries INC. | $184.21 | 2020-2024 | Ilumya |
| Misonix INC | $114.91 | 2021 | |
| Incyte Corporation | $81.41 | 2023-2024 | Opzelura |
| Genzyme Corporation | $73.42 | 2022-2023 | |
| Journey Medical Corporation | $70.90 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $61.21 | 2023-2025 | Zoryve |
| Solta Medical, A Division of Bausch Health US, LLC | $47.22 | 2020-2022 | |
| Amgen INC. | $33.78 | 2023 | Otezla |
| Revance Therapeutics, INC. | $25.69 | 2024 | Daxxify |
| Novartis Pharmaceuticals Corporation | $25.30 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $24.90 | 2025 | Zelsuvmi |
| Mission Pharmacal Company | $23.60 | 2019 | |
| Lilly USA, LLC | $22.75 | 2023 | Olumiant, Taltz |
| Dermavant Sciences, INC. | $21.19 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.19 | 2019 | |
| Horizon Therapeutics Plc | $18.45 | 2022 | |
| Verrica Pharmaceuticals INC. | $16.87 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Guanche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.